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regimens produce encouraging long term survival, with a low
incidence of GvHD and low toxicity, especially in patients with
early disease. The addition of MEL or TBI reduces RRD, but
increases signiﬁcantly TRM and does not improve survival . Dis-
ease phase remains a major predictor of outcome.
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KEPIVANCE USE IN ALLOGENEIC STEM CELL TRANSPLANTATION
Bayer, R.-L.1, Kim, B.1, John, V.1, Devoe, C.1, Cannon, M.1,
Klocke, J.1, Gissinger, D.1 1North Shore University Hospital, Manhas-
set, NY.
Kepivance (palifermin) is a human keratinocyte growth factor
produced by recombinant DNA technology. Kepivance is indi-
cated to decrease the incidence and duration of severe oral mu-
cositis in patients with hematologic malignancies receiving myelo-
toxic therapy requiring hematopoiectic stem cell support. Graft vs.
host disease remains as one of the major obstacles in allogeneic
stem cell transplantation. The role inﬂammatory cytokines play in
GVHD is well known. It has been postulated that if mucositis can
be lessened , cytokine storm will be less and hopefully GVHD.
When looking at the allogeneic stem cell transplant patients during
2005 and 2006 at our institution a trend for a decrease in severity
of acute GVHD was noted in patients treated with Kepivance (60
mcg / kg). We reviewed 10 patients prior to the institution of
Kepivance and 10 after. Only 6 of 10 patients received all six doses
of the drug. 4 out of 10 received only 5 doses. In both groups 8/10
patients had reduced intensity transplants and 2/10 had fully abla-
tive transplants. Average length of stay was 40 days for those
patients who received the drug and 43 for those who did not.
There did not seem to be any major differances between the
incidence of oral and GI mucositis or in the use of narcotics and IV
antibiotics. 9 out of 10 patients who did not get Kepivance had
neutropenic fever and all 10 with Kepivance did. With respect to
GVHD 3/10 who did not get Kepivance developed acute GVHD
and 2/10 patients who received the drug develped acute GVHD. In
the non Kepivance group 2 patients had grade 3/4 GVHD, and one
had grade 2. In the Kepivance group 2 patients had grade 2
GVHD. In the kepivance group 5 patients completed all planned
methotrexate doses for GVHD prophylaxis, and 8 patients in the
non-kepivance group. This review suggests that Kepivance may
lessen the severity of acute GVHD, but not via the mechanism
described above.
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DIFFERENTIAL REQUIREMENT FOR NKG2D IN THE REJECTION OF
HAPLOMISMATCHED AND MHC-I DEFICIENT BONE MARROW
Benjamin, J.E.1, Lanier, L.L.1 1University of Californa, San Francisco,
San Francisco, CA.
Mouse Natural Killer (NK) cells mediate rejection of MHC-
mismatched or MHC-deﬁcient bone marrow allografts. Coun-
teracting activating and inhibitory signals regulate NK cell
activity. The ability of F1 mice to reject parental bone marrow
(BM) cells (hybrid resistance) has been attributed to the pres-
ence in the recipient of a subset of NK cells that lack inhibitory
receptors for the MHC class I antigens expressed by the donor
cells. Evidence supporting the “missing self” hypothesis of hy-
brid resistance was provided by demonstration that MHC
class-I deﬁcient donor BM is rejected by otherwise syngeneic
recipients. We have previously demonstrated a role for
NKG2D, an activating NK cell receptor, in rejection of Balb/c
(H-2d) parental BM by (Balb/c x C57Bl/6; H-2b/d) F1 (CB6F1)
recipient mice. NKG2D ligands are expressed on the regener-
ating myeloid BM cells in Balb/c and NOD mice but not
substantially on the regenerating C57Bl/6 BM cells. Moreover,
the rejection of Balb/c BM by CB6F1 recipients was blocked by
a neutralizing anti-NKG2D monoclonal antibody. The purpose
of this study was to determine whether NKG2D blockade was
sufﬁcient to prevent rejection of MHC-I deﬁcient BM. Beta-2
microglobulin deﬁcient (B2M-/-) Balb/c or NOD bone marrow
was transplanted into irradiated CB6F1 mice that had been
pretreated with neutralizing antibodies to NKG2D. In contrast
to results with wild-type Balb/c or NOD BM whose rejection
was prevented by anti-NKG2D, B2M-/- donor cells were re-
jected despite NKG2D blockade. Furthermore, syngeneic
MHC class I Balb/c recipients were able to reject B2M-/-
Balb/c donors despite NKG2D blockade. These results suggest
that rejection of MHC class I-bearing BM requires activation
via NKG2D, whereas MHC class I-deﬁcient BM elicit a sufﬁ-
ciently strong NK response that augmentation by NKG2D
signaling is not essential for the rejection. Therefore, the hybrid
resistance model in which MHC class I-bearing BM are used for
transplantation may better reﬂect the situation in human hema-
topoietic stem cell transplantation.
227
DETERMINATION OF ALEMTUZUMAB DOSE FOR REDUCED INTENSITY
CONDITIONING IN ALLOGENEIC TRANSPLANTATION
Bigelow, C.L.1, Elkins, S.L.1, Herrin, V.E.1, Hardy, C.L.1, Files, J.C.1
1University of Mississippi Medical Center, Jackson, MS.
From June, 2002, to August, 2006, our institution utilized
reduced intensity conditioning (RIC) regimens for 40 adult
at-risk older patients or those with comorbid conditions. Ma-
lignancies included multiple myeloma, AML, CML, NHL,
MDS, CLL and one renal cell carcinoma. Thirteen (32%) were
in CR at time of transplant while 27 (68%) had relapsed or
refractory disease. Median age was 50 years (range 24-66) and
median follow-up was eight months (1-36 months). Nine pa-
tients were single antigen or allele mismatches at either A, B or
DR. The other 31 patients were 6/6 or better antigen matches
at A, B and DR. Three RIC regimens were used: ﬂudarabine 30
mg/m2 x 5 days and melphalan 140 mg/m2 x 1 day in all groups,
and Alemtuzumab 20 mg/d x 5 days (protocol 1), x 3 days
(protocol 2), and x 2 days (protocol 3). Twenty-three patients
received MUD products and 17 received MRD products; cell
source was bone marrow (17), PBSC (19), cord blood (one) and
combination products (3). All patients received an adequate
CD34 cell dose or TNC dose (cord blood transplant). GVHD
prophylaxis was tacrolimus tapering after day 100 and myco-
phenolate mofetil tapering after day 30. Determination of the
optimal dose of Alemtuzumab was a goal of this study. All
patients except one achieved a WBC graft. Relapse or disease
progression occurred in only 37% of protocol 3, 40% of pro-
tocol 2 and 67% of protocol 1. Although Alemtuzumab dose was
given in a standard fashion not adjusted for body weight or
surface area it was found that lack of consideration of patient
size did not represent the intent of the given protocols. Weight-
based Alemtuzumab dose adjustment showed that a much
broader dose range than expected had occurred. Those receiv-
ing protocol 1 were in a dose range of 1.01-1.90 mg/kg; for
protocol 2 the range was 0.36-1.08 mg/kg; for protocol 3 the
range was 0.36-0.70, overlapping the previous group. The me-
dian dose of Alemtuzumab for the cohort was 0.68 mg/kg. A
clustering of acute GVHD grades I-II appeared below the
median dose at approximately 0.55 mg/kg; only one patient had
grade IV acute GVHD. In summary, formulation of a condi-
tioning protocol that balances engraftment and recurrence of
primary disease on the backdrop of a newly reconstituted im-
mune system is problematic. These data indicate that using the
patient’s body weight in the determination of an optimal Ale-
mtuzumab dose is a more reasonable approach to developing
and standardizing RIC protocols with this drug.
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NONMYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
(NST) FOR HEMATOLOGIC MALIGNANCIES (HM) USING PENTOSTATIN/
LOW-DOSE TOTAL BODY IRRADIATION (PT-TBI)
Bociek, R.G.1, Talmadge, J.E.1, Loberiza, F.1, Kuszynski, C.A.1,
Bierman, P.J.1, Vose, J.M.1, Devetten, M.P.1, Maness, L.J.1,
Armitage, J.O.1, Joshi, S.1, Wisecarver, J.L.1, Enke, C.A.1,
McGuire, T.1, Bernal, K.1, Pavletic, S.Z.2 1University of Nebraska
Medical Center, Omaha, NE; 2National Institutes of Health, Washing-
ton, DC.
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Patients and Methods: Between 10/04 and 6/06, 24 patients
(pts) with high risk/relapsed/refractory hematologic malignan-
cies have undergone NST using a modiﬁcation of our original
Pt-TBI regimen. The median age was 60 years. The median
number of prior therapies was 2 (range 0-6). Diseases trans-
planted included acute lymphoblastic leukemia (n3), myelo-
dysplastic syndrome (n2), acute myelogenous leukemia (n8),
chronic lymphocytic leukemia (n3), indolent non-Hodgkin’s
lymphoma (n2), and mantle cell lymphoma (n6). Condition-
ing consisted of Pentostatin 4 mg/m2 daily on day -10, -9, and
-8, followed by 200 cGy TBI on day -1. Post-grafting immu-
nosuppression consisted of cyclosporine/mycophenolate
mofetil. Results: Transplantation was performed using mobi-
lized progenitor cells from matched related (n8) or unrelated
(n16) donors. Death prior to 100 days post transplant oc-
curred in 4 unrelated donor transplants. The median nadir
values for hemoglobin, neutrophil count and platelet count were
8.9 g/dl (range 7.6-13.7), 300/mm3 (range 0-1900), and 63/mm3
(range 9-165) respectively. Primary graft failure/autologous re-
covery occurred in one patient with mantle cell lymphoma. The
median values for CD3 cells and WBC at day 28 were 85%
and 90% donor cells respectively. The analogous median values
at day 70 were 85% and 100% respectively. One pt with a
myelproliferative disorder and thalidomide as his only prior
therapy experienced late graft failure despite donor lymphocyte
infusions. The cumulative incidence of grade II-IV acute graft-
versus-host disease was approximately 54% (14% in related
versus 68% in unrelated donors, P0.08). The probability of
extensive chronic graft-versus-host disease in patients surviving
beyond 100 days is 38%. The cumulative incidence of relapse at
one year post transplant is 43%. The one year probabilities of
event-free and overall survival are 41% and 61% respectively.
Conclusions: This modiﬁcation of our original Pt-TBI regi-
men continues to demonstrate fairly minimal regimen related
toxicity, although as expected hematologic toxicity appears to be
more signiﬁcant than with our prior day -21 Pentostatin regi-
men. Graft versus host disease continues to be a major cause of
morbidity/mortality, particularly in unrelated donor trans-
plants. Further studies will concentrate on attempting to de-
crease the incidence of acute and chronic graft versus host
disease through the use of T-cell depletion with in vitro ale-
mtuzumab.
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UMBILICAL CORD BLOOD TRANSPLANTATION FOR ADULT PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
Brunstein, C.1, Setubal, D.1, DeFor, T.1, Weisdorf, D.1, McGlave, P.1,
Miller, J.1, Wagner, J.1 1University of Minnesota Blood and Marrow
Transplant Program, Minneapolis, MN.
Chronic myelogenous leukemia (CML) was primarily treated
with HSCT until imatinib mesilate was shown to be effective
and safe for patients with early chronic phase CML. However,
patients who fail imatinib therapy due to disease progression or
drug intolerance still require HSCT. Umbilical cord blood
(UCB) has been an increasingly used source of hematopoietic
stem cells for transplantation (HSCT) of patients with hemato-
logic malignancies who lack a suitable sibling donor. We report
here on 20 adult patients who underwent UCB transplantation
(UCBT) for Ph CML at the University of Minnesota between
1998 and 2005. Patient received myeloablative (MA, n12) or
nonmyeloablative (NMA, n8) conditioning, The median age
was 46 y (r: 18-58), 12 (60%) were male, and median weight was
78 kg (r: 57-103), and 13 (65%) were CMV positive. The MA
conditioning was Bu/Cy (n2) Cy/TBI  ATG (n4), or Cy/
Fludarabine(Flu)/TBI (n6). The NMA conditioning was Bu/
Flu/TBI (n2) or Cy/Flu/TBI ATG (n6). Posttransplanta-
tion immunosuppression was CsA alone (n1), CsA/
methylprednisolone(MP) (n5), or CsA/MMF (n14). Eleven
patients (55%) receive a double UCB graft. The highest HLA
disparity of UCB units was 4/6 (n13), 5/6 (n5), and 6/6
(n2). Six patients (30%) were in ﬁrst chronic phase (CP1) and
14 (70%) were in accelerated phase (AP) CML. The median
TNC dose infused was 2.9  107/kg (r:1.2-5.3) and median
CD34 dose infused was 4.8  105/kg (r: 0.7-12.7). The median
time from diagnosis to transplant was 24.5 months (r: 6.7-
118.8), and the median follow-up of surviving patients was 2.9
yrs (r: 0.7-.7.0). There were no failures of neutrophil engraft-
ment. In the MA setting median time to neutrophil engraftment
was 21d (r:13-33), grade II-IV acute GVHD was 58% (95%CI,
28-88%), 1-yr transplant related mortality (TRM) 41%
(95%CI, 13-69), 2-yr relapse rate 10% (95%CI, 0-26), and
overall survival 58% (95%CI, 30-86). In the NMA setting me-
dian time to neutrophil engraftment was 13d (r:5-32), grade
II-IV acute GVHD was 63% (95%CI, 28-98%), 1-yr transplant
related mortality (TRM) 38% (95%CI, 6-70), 2-yr relapse rate
13% (95%CI, 0-34), and overall survival 50% (95%CI, 15-85).
There was no statistically signiﬁcant difference between MA and
NMA conditioning regimens on all outcomes. In this report we
show that UCB appears to be a safe and effective HSC for
transplantation of patients with CML.
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FLUDARABINE/FULL DOSE I.V. BUSULFAN CONDITIONING REGIMEN IN
ALLOGENEIC PBSC TRANSPLANTATION FOR HIGH RISK PATIENTS
Chunduri, S.1, Dobogai, L.C.1, Peace, D.1, Saunthararajah, Y.1,
Quigley, J.1, Chen, Y.-H.1, Boccuni, P.1, Hoffman, R.1, Mahmud, N.1,
Beri, R.1, Hurter, E.1, Rondelli, D.1 1Section of Hematology/Oncology,
University of Illinois at Chicago, Chicago, IL.
Fludarabine/ full dose busulfan (FluBu) conditioning regimen
causes moderate extrahematologic toxicity and low rates of acute
graft-versus-host disease (GVHD) in allogeneic hematopoietic
stem cell transplantation (HSCT).
In this study we utilized this regimen in 21 adult patients with
hematologic malignancies, including 15 patients (71%) at high risk
of relapse (8 acute leukemia in relapse, 3 NHL in relapse, 1 NHL
in CR2, 1 myeloﬁbrosis in transformation, 2 CML-AP resistant to
imatinib) and 6 patients at standard risk (3 AML in CR1, 2
CML-CP resistant to imatinib, 1 MDS). All patients were prepared
with ﬂudarabine (30 or 40 mg/m2/day) for 4 days from d-9 to d-6
and i.v. busulfan (3.2 mg/kg/day) for 4 days from d-5 to d-2, and
received an HLA matched related (n14) or unrelated (n7)
peripheral blood stem cell (PBSC) transplant. Mean number of
CD34 cells infused was 7.34.0  106/kg. Thymoglobulin was
added to the preparative regimen on d -3 to d-1 in 9 patients,
including those receiving an unrelated HSCT. Acute GVHD pro-
phylaxis included standard tacrolimus and methotrexate on d1, d3,
d6 and d11. All patients fully engrafted but one ALL patient
transplanted in relapse who recovered with leukemic blasts. Me-
dian times to ANC 0.5109/L and platelet 20109/L were 15d
(range: 18-24) and 13d (range: 0-24), respectively. Acute GVHD
grade II-IV was observed in 24% of the patients (grade III-IV
18%) and chronic GVHD in 9 of 14 evaluable patients (64%). Of
21 patients, 8 died in full relapse with bacterial or fungal infection
and 2 for acute GVHD grade III and fungal infection. Median time
to relapse after HSCT was 72d (range: 18-328). At a median
follow-up of 447 d (range: 120-1196) for patients who are alive, the
overall survival (OS) and event-free survival (EFS) are 52% and
48%, respectively. In the group at high risk the OS and EFS are
both 33% at 447 d median follow-up (range: 147-834).
FluBu conditioning regimen, besides causing low transplant-
related morbidity and mortality, is also effective in high risk pa-
tients receiving an allogeneic PBSC transplant from related or
unrelated donors.
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HAPLOIDENTICAL NON-MYELOABLATIVE HEMATOPOIETIC TRANS-
PLANT WITH SIROLIMUS BASED IMMUNOSUPPRESSION YIELDS RELI-
ABLE ENGRAFTMENT AND MAY RESULT IN LONG TERM SURVIVAL
Claxton, D.F.1, Creme, L.1, Ehmann, W.C.1, Rybka, W.B.1 1Penn
State Cancer Institute, Hershey, PA.
Timely availability of matched donors limits allo-hematopoi-
etic transplant (HCT) options for many otherwise suitable pa-
tients. We have explored sirolimus (rapamycin) based immuno-
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